Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2015

View Archived Issues

Yabao Pharmaceutical and Primary Peptides to collaborate on peptide therapeutics for stroke

AntriaBio confirms new product candidate, AB-301, for type 2 diabetes

EnGeneIC to begin U.S. phase I study of (EGFR)-EDV-dox

Otsuka launches Olanedine antiseptic

Aerie Pharmaceuticals reports phase III efficacy data for Rhopressa

New mutation in LYRM7 gene associated with complex III deficiency

Nurix collaborates with Celgene on therapies to modulate protein homeostasis

AB Science's masitinib receives FDA orphan drug designation for gastric cancer

Ajinomoto patents MOGAT2 inhibitors

Arizona State University discloses RXR agonists

Toray Industries reports development of ROR-gamma antagonists

Memorial Sloan Kettering and Illumina collaborate on circulating tumor DNA

British scientists develop CDK7 inhibitors

Janssen Pharmaceutica synthesizes CB1 inverse agonists

Mitobridge signs sponsored research agreement for its PPARdelta modulators

New malaria vaccine trial shows lack of efficacy

Proof-of-concept study shows promise of novel antimalarial KAF-156

Amgen agrees to acquire TA-8995 developer Dezima Pharma

Prolyl oligopeptidase inhibitor shows promise for cognitive deficit associated with schizophrenia

Ignyta starts phase I trial of RXDX-107 in patients with solid tumors

Dimension Therapeutics' hemophilia B gene therapy receives FDA fast track designation

Phase I/IIa results presented for ChAd-EBO-Z Ebola vaccine

FDA grants orphan drug designation to sephin-1 for the treatment of Charcot-Marie-Tooth disease

Hypoglycemia may be detected by analyzing exhaled breath

FDA awards fast track designation to Can-Fite's CF-102 for hepatocellular carcinoma

Ventrix initiates phase I trial of VentriGel in patients following myocardial infarction

FDA approves Vraylar for bipolar disorder and schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...